Stroke | Jotup

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Angiology, Medical specialties, Cardiovascular system, Vascular diseases, Carotid artery stenosis, Neurosurgery, Vascular surgery, Stenosis, Common carotid artery, Stroke, Carotid ultrasonography, Carotid stenting

Thursday, January 14, 2021 - 8:04am

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points:

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Thursday, January 14, 2021 - 4:58am

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points:

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy

Clinical research, Drug Safety, Food and Drug Administration, Investigational New Drug, Stroke, Health

Tuesday, January 12, 2021 - 1:15pm

PHOENIX, Jan. 12, 2021 /PRNewswire/ --(OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) requesting clearance to initiate the first clinical trial using cellular immunotherapy for treatment of stroke.

Key Points:

PHOENIX, Jan. 12, 2021 /PRNewswire/ --(OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) requesting clearance to initiate the first clinical trial using cellular immunotherapy for treatment of stroke.
"The uniqueness of the ImmCelz approach is that the immunological cells used are derived from the same patient to which they are administered."
"We have previously reported potent reduction of stroke infarct volume, as well as post-stroke behavioral improvements in animals treated with ImmCelz.
See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov .

Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy

Neurotrauma, Medical specialties, Cerebrovascular diseases, Stroke, Branches of biology, Medicine, Intracerebral hemorrhage, Medical diagnosis, Bleeding

Monday, January 11, 2021 - 12:00pm

Amydis has reached agreement with the FDA on both nonclinical and clinical plans.

Key Points:

Amydis has reached agreement with the FDA on both nonclinical and clinical plans.
CAA is a major cause of spontaneous intracerebral hemorrhage in people older than 55 and an important contributor to age-related cognitive decline.
I am keenly aware of the challenges CAA patients face in the diagnosis and treatment of disease.
I believe that diagnosis of CAA through the eye would be a tremendous step forward for the field.

Zynex Announces a Second Utility Patent for Its Blood Volume Monitor

Zynex, Medical specialties, Medicine, Health care, Cardiac monitoring, Stroke, Monitoring, Draft:Thomas Sandgaard

Wednesday, January 6, 2021 - 2:15pm

(NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported it has obtained a second U.S. Utility patent for its Blood Volume Monitor Device.

Key Points:

(NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today reported it has obtained a second U.S. Utility patent for its Blood Volume Monitor Device.
Thomas Sandgaard, the inventor, has assigned the patent to Zynex's subsidiary, Zynex Monitoring Solutions.
Thomas Sandgaard, CEO of Zynex said: "I am excited to receive additional patent protection for our non-invasive blood volume/blood loss technology.
Zynex also has a blood volume monitor for use in hospitals and surgery centers.

PEN FRAUD INVESTIGATION: Hagens Berman Encourages Penumbra (PEN) Investors to Contact the Firm, Investigation Expanded to Cover More Recent Claims of Fraud

Penumbra, Hagens, Stroke, Steve Berman, Articles

Tuesday, January 5, 2021 - 9:32pm

SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Penumbra, Inc. (NYSE: PEN) investors to submit their losses now .

Key Points:

SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges Penumbra, Inc. (NYSE: PEN) investors to submit their losses now .
The investigation centers on whether Penumbra misled investors about the companys flagship products for treating ischemic stroke.
Were focused on investor losses and whether Penumbra misled investors about the Jet 7 devices safety, said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you are a Penumbra investor or have information that may assist our investigation, click here to discuss your legal rights with Hagens Berman .

PEN INVESTOR UPDATE: Hagens Berman, National Trial Attorneys, Expands Penumbra (PEN) Investigation to Cover More Recent Claims of Fraud, Encourages Investors to Contact its Attorneys Now

Penumbra, Steve Berman, Hagens, Stroke, Citigroup, Economy of New York City, Companies, Articles

Thursday, December 31, 2020 - 12:12am

SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Penumbra, Inc. (NYSE: PEN) investors to submit their losses now .

Key Points:

SAN FRANCISCO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Hagens Berman urges Penumbra, Inc. (NYSE: PEN) investors to submit their losses now .
The investigation centers on whether Penumbra misled investors about the companys flagship products for treating ischemic stroke.
Were focused on investor losses and whether Penumbra misled investors about the Jet 7 devices safety, said Reed Kathrein, the Hagens Berman partner leading the investigation.
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys.

PEN SHAREHOLDER ALERT: Hagens Berman, National Trial Attorneys, Continues Penumbra (PEN) Fraud Investigation In Light Of Company’s Admissions, Encourages Investors to Contact its Attorneys Now

Penumbra, Stroke, Articles

Tuesday, December 22, 2020 - 4:14pm

The investigation centers on whether Penumbra misled investors about the companys flagship products for treating ischemic stroke.

Key Points:

The investigation centers on whether Penumbra misled investors about the companys flagship products for treating ischemic stroke.
On Nov. 9, 2020, Quintessential Capital Management (QCM) published a scathing report, Penumbra and its killer catheter.
Later that day, Penumbra admitted its co-founder, Arani Bose, was the real author of published scientific literature supportive of the companys activities.
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys.

ReWalk Robotics Donates ReStore Exo-Suit to Brooks Rehabilitation to Support Stroke Survivors

Robotics, Health, Assistive technology, Articles, Medical robotics, Prosthetics, Powered exoskeleton, ReWalk, Physical medicine and rehabilitation, Stroke recovery, Stroke

Monday, December 21, 2020 - 9:45pm

Brooks combines highly trained clinicians with the latest technologies to advance rehabilitation through innovation and research-based practices.

Key Points:

Brooks combines highly trained clinicians with the latest technologies to advance rehabilitation through innovation and research-based practices.
Thanks to this donation, we are able to offer our patients additional options for their stroke recovery," said Robert McIver, PT, DPT, NCS, Director of Clinical Technology at Brooks Rehabilitation.
ReWalk Robotics Ltd.develops, manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.
For 50 years, Brooks Rehabilitation, headquartered in Jacksonville, Fla., has been a comprehensive source for physical rehabilitation services.

Stroke and Altered Mental State Increase Risk of Death for COVID-19 Patients

Aging-associated diseases, Coronavirus disease, Occupational safety and health, Zoonoses, Stroke, Health, Hypertension, Branches of biology, Articles, Silent stroke, Perinatal stroke

Friday, December 18, 2020 - 9:16pm

These findings have the potential to identify and focus treatment efforts on individuals most at risk and could decrease COVID-19 deaths.

Key Points:

These findings have the potential to identify and focus treatment efforts on individuals most at risk and could decrease COVID-19 deaths.
These individuals were compared with 1,743 non-neurological COVID-19 patients of similar age and disease severity who were admitted during the same period.
Among people who underwent brain imaging, 55 were diagnosed with stroke and 258 people exhibited confusion or altered thinking ability.
More than half the stroke patients in the study did not have hypertension or other underlying risk factors for stroke.